Worth reading
42Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
688000
Shares (ordinary shares underlying the stock acquisition rights, total)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of stock acquisition rights (stock options) offered
発行・処分する株式数
19th series: 654,000 ordinary shares; 20th series: 27,000 ordinary shares; 21st series: 7,000 ordinary shares
Intended allottee
Category The Company's directors, executive officers and employees, and directors and employees of the Company's subsidiaries / Number of Employees 54 / Number of stock acquisition rights 6,540 rights, Category The Company's executive officers and employees, and directors of the Company's subsidiaries / Number of Employees 23 / Number of stock acquisition rights 270 rights, Category Employees of the Company and employees of the Company's subsidiaries / Number of Employees 2 / Number of stock acquisition rights 70 rights
Terms of the stock acquisition rights
Exercise price
19th series: ¥321,500 per stock acquisition right (¥3,215 per share). 20th and 21st series: Not disclosed
Number of Stock Acquisition Rights
Total issued: 6,540 rights for the 19th series, 270 rights for the 20th series, and 70 rights for the 21st series. Outstanding unexercised rights: Not disclosed
Categories and Number of Persons Covered
19th series: 54 of the Company's directors, executive officers and employees, and the directors and employees of the Company's subsidiaries; 6,540 rights. 20th series: 23 of the Company's executive officers and employees, and the directors of the Company's subsidiaries; 270 rights. 21st series: 2 of the Company's employees and the employees of the Company's subsidiaries; 70 rights
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of stock acquisition rights (stock options) offered |
| Number of shares to be issued or disposed of | 19th series: 654,000 ordinary shares; 20th series: 27,000 ordinary shares; 21st series: 7,000 ordinary shares |
| Intended allottee | Category The Company's directors, executive officers and employees, and directors and employees of the Company's subsidiaries / Number of Employees 54 / Number of stock acquisition rights 6,540 rights, Category The Company's executive officers and employees, and directors of the Company's subsidiaries / Number of Employees 23 / Number of stock acquisition rights 270 rights, Category Employees of the Company and employees of the Company's subsidiaries / Number of Employees 2 / Number of stock acquisition rights 70 rights |
| Exercise price | 19th series: ¥321,500 per stock acquisition right (¥3,215 per share). 20th and 21st series: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 6,540 rights for the 19th series, 270 rights for the 20th series, and 70 rights for the 21st series. Outstanding unexercised rights: Not disclosed |
| Categories and Number of Persons Covered | 19th series: 54 of the Company's directors, executive officers and employees, and the directors and employees of the Company's subsidiaries; 6,540 rights. 20th series: 23 of the Company's executive officers and employees, and the directors of the Company's subsidiaries; 270 rights. 21st series: 2 of the Company's employees and the employees of the Company's subsidiaries; 70 rights |
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Previously undecided matters relating to the issuance approved by the Board of Directors on 25 June 2026 have been finalized.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.